|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Effects of Pioglitazone on Adipose Tissue Remodeling Within the Setting of Obesity and Insulin Resistance
1 Department of Metabolic and Cardiovascular Diseases and
2 Core Technologies, Novartis Institute of Biomedical Research, Novartis Pharmaceutical, Summit, New Jersey
Obesity and dysfunctional energy partitioning can lead to the development of insulin resistance and type 2 diabetes. The antidiabetic thiazolidinediones shift the energy balance toward storage, leading to an increase in whole-body adiposity. These studies examine the effects of pioglitazone (Pio) on adipose tissue physiology, accumulation, and distribution in female Zucker (fa/fa) rats. Pio treatment (up to 28 days) decreased the insulin-resistant and hyperlipidemic states and increased food consumption and whole-body adiposity. Magnetic resonance imaging (MRI) analysis and weights of fat pads demonstrated that the increase in adiposity was not only limited to the major fat depots but also to fat deposition throughout the body. Adipocyte sizing profiles, fat pad histology, and DNA content show that Pio treatment increased the number of small adipocytes because of both the appearance of new adipocytes and the shrinkage and/or disappearance of existing mature adipocytes. The remodeling was time dependent, with new small adipocytes appearing in clusters throughout the fat pad, and accompanied by a three- to fourfold increase in citrate synthase and fatty acid synthase activity. The appearance of new fat cells and the increase in fat mass were depot specific, with a rank order of responsiveness of ovarian > retroperitoneal > subcutaneous. This differential depot effect resulted in a redistribution of the fat mass in the abdominal region such that there was an increase in the visceral:subcutaneous ratio, as confirmed by MRI analysis. Although the increased adiposity is paradoxical to an improvement in insulin sensitivity, the quantitative increase of adipose mass should be viewed in context of the qualitative changes in adipose tissue, including the remodeling of adipocytes to a smaller size with higher lipid storage potential. This shift in energy balance is likely to result in lower circulating free fatty acid levels, ultimately improving insulin sensitivity and the metabolic state.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  P. M. Rogers, N. Mashtalir, M. A. Rathod, O. Dubuisson, Z. Wang, K. Dasuri, S. Babin, A. Gupta, N. Markward, W. T. Cefalu, et al. Metabolically Favorable Remodeling of Human Adipose Tissue by Human Adenovirus Type 36 Diabetes, September 1, 2008; 57(9): 2321 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Q. Wang, W. T. Cefalu, X. H. Zhang, Y. Yu, J. Qin, L. Son, P. M. Rogers, N. Mashtalir, J. R. Bordelon, J. Ye, et al. Human Adenovirus Type 36 Enhances Glucose Uptake in Diabetic and Nondiabetic Human Skeletal Muscle Cells Independent of Insulin Signaling Diabetes, July 1, 2008; 57(7): 1805 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hellmold, H. Zhang, U. Andersson, B. Blomgren, T. Holland, A.-L. Berg, M. Elebring, N. Sjogren, K. Bamberg, B. Dahl, et al. Tesaglitazar, a PPAR{alpha}/{gamma} Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats Toxicol. Sci., July 1, 2007; 98(1): 63 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koska, E. Ortega, C. Bogardus, J. Krakoff, and J. C. Bunt The effect of insulin on net lipid oxidation predicts worsening of insulin resistance and development of type 2 diabetes mellitus Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E264 - E269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Buchmann, C. Meyer, S. Neschen, R. Augustin, K. Schmolz, R. Kluge, H. Al-Hasani, H. Jurgens, K. Eulenberg, R. Wehr, et al. Ablation of the Cholesterol Transporter Adenosine Triphosphate-Binding Cassette Transporter G1 Reduces Adipose Cell Size and Protects against Diet-Induced Obesity Endocrinology, April 1, 2007; 148(4): 1561 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, and Y. Deshaies Involvement of adipose tissues in the early hypolipidemic action of PPAR{gamma} agonism in the rat Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1408 - R1417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lobo, B. M. Wiczer, A. J. Smith, A. M. Hall, and D. A. Bernlohr Fatty acid metabolism in adipocytes: functional analysis of fatty acid transport proteins 1 and 4 J. Lipid Res., March 1, 2007; 48(3): 609 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Sharma and B. Staels Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Utzschneider and S. E. Kahn The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, J. P. Berger, and Y. Deshaies Mechanisms of the Depot Specificity of Peroxisome Proliferator-Activated Receptor {gamma} Action on Adipose Tissue Metabolism. Diabetes, October 1, 2006; 55(10): 2771 - 2778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grun, H. Watanabe, Z. Zamanian, L. Maeda, K. Arima, R. Cubacha, D. M. Gardiner, J. Kanno, T. Iguchi, and B. Blumberg Endocrine-Disrupting Organotin Compounds Are Potent Inducers of Adipogenesis in Vertebrates Mol. Endocrinol., September 1, 2006; 20(9): 2141 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Pietilainen, K. Kannisto, E. Korsheninnikova, A. Rissanen, J. Kaprio, E. Ehrenborg, A. Hamsten, and H. Yki-Jarvinen Acquired Obesity Increases CD68 and Tumor Necrosis Factor-{alpha} and Decreases Adiponectin Gene Expression in Adipose Tissue: A Study in Monozygotic Twins J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2776 - 2781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Araki, T. Masaki, I. Katsuragi, K. Tanaka, T. Kakuma, and H. Yoshimatsu Telmisartan Prevents Obesity and Increases the Expression of Uncoupling Protein 1 in Diet-Induced Obese Mice Hypertension, July 1, 2006; 48(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Sentinelli, E Filippi, M G Cavallo, S Romeo, M Fanelli, and M G Baroni The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPAR{gamma} agonist restores normal cell signaling and differentiation J. Endocrinol., February 1, 2006; 188(2): 271 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Velliquette, J. E. Friedman, J. Shao, B. B. Zhang, and P. Ernsberger Therapeutic Actions of an Insulin Receptor Activator and a Novel Peroxisome Proliferator-Activated Receptor {gamma} Agonist in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 422 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. M. Coort, W. A. Coumans, A. Bonen, G. J. van der Vusse, J. F. C. Glatz, and J. J. F. P. Luiken Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats J. Lipid Res., June 1, 2005; 46(6): 1295 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith Pioglitazone Induces Mitochondrial Biogenesis in Human Subcutaneous Adipose Tissue In Vivo Diabetes, May 1, 2005; 54(5): 1392 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Boden, C. Homko, M. Mozzoli, L. C. Showe, C. Nichols, and P. Cheung Thiazolidinediones Upregulate Fatty Acid Uptake and Oxidation in Adipose Tissue of Diabetic Patients Diabetes, March 1, 2005; 54(3): 880 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-K. Hyun, I.-Y. Kim, and S. C. Frost Soluble Fibroin Enhances Insulin Sensitivity and Glucose Metabolism in 3T3-L1 Adipocytes J. Nutr., December 1, 2004; 134(12): 3257 - 3263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Berthiaume, H. Sell, J. Lalonde, Y. Gelinas, A. Tchernof, D. Richard, and Y. Deshaies Actions of PPAR{gamma} agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1116 - R1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boden and M. Laakso Lipids and Glucose in Type 2 Diabetes: What is the cause and effect? Diabetes Care, September 1, 2004; 27(9): 2253 - 2259. [Full Text] [PDF]
|
|
|
|
|
|
I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith The Effect of Pioglitazone on Peroxisome Proliferator-Activated Receptor-{gamma} Target Genes Related to Lipid Storage In Vivo Diabetes Care, July 1, 2004; 27(7): 1660 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]
|
|
|
|
|
|
S. Shadid and M. D. Jensen Effects of Pioglitazone Versus Diet and Exercise on Metabolic Health and Fat Distribution in Upper Body Obesity Diabetes Care, November 1, 2003; 26(11): 3148 - 3152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Creager, T. F. Luscher, F. Cosentino, and J. A. Beckman Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I Circulation, September 23, 2003; 108(12): 1527 - 1532. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Larsen, P. B. Jensen, R. V. Sorensen, L. K. Larsen, N. Vrang, E. M. Wulff, and K. Wassermann Differential Influences of Peroxisome Proliferator-Activated Receptors{gamma} and -{alpha} on Food Intake and Energy Homeostasis Diabetes, September 1, 2003; 52(9): 2249 - 2259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rossmeisl, J. S. Rim, R. A. Koza, and L. P. Kozak Variation in Type 2 Diabetes-Related Traits in Mouse Strains Susceptible to Diet-Induced Obesity Diabetes, August 1, 2003; 52(8): 1958 - 1966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laplante, H. Sell, K. L. MacNaul, D. Richard, J. P. Berger, and Y. Deshaies PPAR-{gamma} Activation Mediates Adipose Depot-Specific Effects on Gene Expression and Lipoprotein Lipase Activity: Mechanisms for Modulation of Postprandial Lipemia and Differential Adipose Accretion Diabetes, February 1, 2003; 52(2): 291 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kuhlmann, C. Neumann-Haefelin, U. Belz, J. Kalisch, H.-P. Juretschke, M. Stein, E. Kleinschmidt, W. Kramer, and A. W. Herling Intramyocellular Lipid and Insulin Resistance: A Longitudinal In Vivo 1H-Spectroscopic Study in Zucker Diabetic Fatty Rats Diabetes, January 1, 2003; 52(1): 138 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Albrektsen, K. S. Frederiksen, W. E. Holmes, E. Boel, K. Taylor, and J. Fleckner Novel Genes Regulated by the Insulin Sensitizer Rosiglitazone During Adipocyte Differentiation Diabetes, April 1, 2002; 51(4): 1042 - 1051. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |